晚期卵巢癌新辅助化疗研究进展  

Research progress in neoadjuvant chemotherapy for advanced ovarian cancer

作　　者：胡柯[1] 狄文[1] 

机构地区：[1]上海交通大学医学院仁济医院妇产科,上海200127

出　　处：《上海交通大学学报（医学版）》2008年第5期592-595,共4页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：目前卵巢癌的标准治疗方案是以手术为主,辅以术后化疗,实现满意肿瘤细胞减灭术是手术的目的。但患者出现明显症状时,疾病大多已处于晚期,多数患者无法实行满意肿瘤细胞减灭术。新辅助化疗结合间隔手术作为晚期卵巢癌患者的替代治疗方案具有较好的应用前景。文章就晚期卵巢癌新辅助化疗的研究进展作一综述。The standard treatment of advanced ovarian cancer includes primary cytoreductive （debulking） surgery followed by chemotherapy aiming at optimal residual tumor volumes. As the majority of patients with ovarian cancer have been in advanced stage at presentation, optimal surgery couldn＇t be achieved in large number of patients. As a promising alternative to standard primary surgery, neoadjuvant chemotherapy followed by interval surgical debulking is likely to be applicable in practice. This review gives an introduction on the research progress in neoadjuvant chemotherapy for advanced ovarian cancer.

关 键 词：卵巢癌 新辅助化疗 间隔手术 满意肿瘤细胞减灭术 预后 

分 类 号：R737.31[医药卫生—肿瘤]